PureTech Health

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for conditions with significant unmet needs. The company's approach emphasizes the creation of therapies that offer oral bioavailability, which allows for effective drug delivery while minimizing first-pass metabolism and reducing the risk of hepatotoxicity and other side effects. By addressing these critical challenges, Seaport Therapeutics aims to improve the quality of life for patients living with neuropsychiatric disorders.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines for conditions with significant unmet needs. The company's approach emphasizes the creation of therapies that offer oral bioavailability, which allows for effective drug delivery while minimizing first-pass metabolism and reducing the risk of hepatotoxicity and other side effects. By addressing these critical challenges, Seaport Therapeutics aims to improve the quality of life for patients living with neuropsychiatric disorders.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Sonde Health is a digital medicine company focused on developing voice-based technologies for monitoring and diagnosing mental and respiratory health. The company's innovative platform utilizes mobile devices to capture and analyze subtle changes in voice, allowing for the creation of various health measurements related to brain, muscle, and respiratory function. By enabling users to track changes in their health over time, Sonde Health aims to identify early signs of disease, ultimately transforming the approach to health monitoring and diagnosis.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed to treat acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, thereby allowing for selective targeting of cancer cells while sparing normal cells. This innovative approach aims to minimize the toxicities associated with traditional immunotherapies, such as bispecific antibodies and CAR T cells, which often affect both cancerous and healthy cells. Vor Biopharma's mission is to provide safer and more effective treatment options for patients with hematological malignancies by creating therapies that protect healthy, functional cells from depletion during targeted cancer treatments.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing innovative therapies for neuropsychiatric disorders and pain management. The company is advancing its lead product candidate, KarXT, an oral modulator that has completed a Phase II clinical trial for acute psychosis in schizophrenia and is undergoing Phase Ib trials for various central nervous system disorders, including the cognitive and negative symptoms associated with schizophrenia, Alzheimer's disease, and dementia-related psychosis. Karuna Therapeutics is also actively developing a pipeline of muscarinic-targeted drug candidates to address unmet medical needs in these challenging areas. Founded in 2009, the company has established partnerships and licensing agreements to support its drug discovery efforts and to enhance its research capabilities.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in developing innovative therapies for neuropsychiatric disorders and pain management. The company is advancing its lead product candidate, KarXT, an oral modulator that has completed a Phase II clinical trial for acute psychosis in schizophrenia and is undergoing Phase Ib trials for various central nervous system disorders, including the cognitive and negative symptoms associated with schizophrenia, Alzheimer's disease, and dementia-related psychosis. Karuna Therapeutics is also actively developing a pipeline of muscarinic-targeted drug candidates to address unmet medical needs in these challenging areas. Founded in 2009, the company has established partnerships and licensing agreements to support its drug discovery efforts and to enhance its research capabilities.

resTORbio, Inc., founded in 2016 and headquartered in Boston, Massachusetts, was a clinical-stage biopharmaceutical company focused on developing medicines to treat aging-related diseases. Its primary approach involved selectively inhibiting the target of rapamycin complex 1 (TORC1), a pathway linked to age-related decline in organ functions. The company's lead drug candidate, RTB101, an oral and potent TORC1 inhibitor, was being evaluated in Phase 1b/2a clinical trials for Parkinson's disease and other neurodegenerative diseases. Prior to its acquisition by Adicet Bio in September 2020, resTORbio collaborated with TrialSpark to investigate RTB-101 as a potential treatment for COVID-19.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. Founded in 2006, Gelesis utilizes a mechanobiology technology platform to create first-in-class therapeutics. Its flagship product, PLENITY, is an FDA-cleared, orally administered aid for weight management, comprised of hydrogel particles that expand in the stomach to promote a feeling of fullness and help reduce caloric intake. The company's pipeline also includes potential treatments for non-alcoholic fatty liver disease, type 2 diabetes, and chronic idiopathic constipation, addressing a range of metabolic and digestive health issues.

Tal Medical, Inc. is a clinical stage neuroscience company based in Boston, Massachusetts, specializing in the development of non-invasive neurostimulation treatments for psychiatric and neurological disorders. Founded in 2010, the company has licensed its innovative Low Field Magnetic Stimulation (LFMS) technology, which produces a sub-threshold electric field to modulate brain circuitry associated with unipolar and bipolar depression. This technology aims to address significant unmet clinical needs in treating major depressive disorder and bipolar depression, conditions for which existing therapies often fall short and can entail considerable side effects. By focusing on non-contact neuromodulatory devices, Tal Medical seeks to enhance treatment efficacy and improve patient outcomes in brain disorders.

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. Founded in 2006, Gelesis utilizes a mechanobiology technology platform to create first-in-class therapeutics. Its flagship product, PLENITY, is an FDA-cleared, orally administered aid for weight management, comprised of hydrogel particles that expand in the stomach to promote a feeling of fullness and help reduce caloric intake. The company's pipeline also includes potential treatments for non-alcoholic fatty liver disease, type 2 diabetes, and chronic idiopathic constipation, addressing a range of metabolic and digestive health issues.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

Follica, Inc. is a Boston-based company focused on developing innovative therapies for hair loss in adults. Established in 2005, Follica specializes in a proprietary treatment system that includes an in-office device designed to disrupt the skin and stimulate the creation of new hair follicles. Additionally, the company offers an at-home treatment system that delivers therapeutic compounds directly to the scalp, facilitating a daily hair care routine. Follica's approach targets conditions related to hair follicles, addressing a market that exceeds $10 billion annually and is characterized by a lack of effective solutions. The company's regenerative biology-based technology aims to not only create new hair follicles but also to thicken existing hair, providing clinicians with effective treatment options for their patients.

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. Founded in 2006, Gelesis utilizes a mechanobiology technology platform to create first-in-class therapeutics. Its flagship product, PLENITY, is an FDA-cleared, orally administered aid for weight management, comprised of hydrogel particles that expand in the stomach to promote a feeling of fullness and help reduce caloric intake. The company's pipeline also includes potential treatments for non-alcoholic fatty liver disease, type 2 diabetes, and chronic idiopathic constipation, addressing a range of metabolic and digestive health issues.

Solace Pharmaceuticals, a Boston based drug company focused on therapeutics for chronic pain.

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. Founded in 2006, Gelesis utilizes a mechanobiology technology platform to create first-in-class therapeutics. Its flagship product, PLENITY, is an FDA-cleared, orally administered aid for weight management, comprised of hydrogel particles that expand in the stomach to promote a feeling of fullness and help reduce caloric intake. The company's pipeline also includes potential treatments for non-alcoholic fatty liver disease, type 2 diabetes, and chronic idiopathic constipation, addressing a range of metabolic and digestive health issues.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.